SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCerillion Regulatory News (CER)

Share Price Information for Cerillion (CER)

Share Price is delayed by 15 minutes
Get Live Data
1,240.00    30.00 (2.46%)
Bid:
1,230.00
Ask:
1,250.00
Spread: 20.00 (1.626%)
Market Cap: £369.26m
CER Live PriceLast checked at - London Stock Exchange

Intraday Cerillion Share Chart

Further concentrate purchase

1 Oct 2007 07:02

Celtic Resources Holdings PLC01 October 2007 1 October 2007 Celtic Resources Holdings Plc ("Celtic" or the "Company") Celtic enters into agreement to purchase concentrates Celtic is pleased to announce that it has entered into an agreement with asubsidiary of European Goldfields Limited, Hellas Gold S.A. ("Hellas Gold"), forthe purchase of 50,000 tonnes of concentrates containing approximately 30,000 ozof gold. As announced on 22 September 2006, the Company acquired 9,000 tonnes ofconcentrate containing approximately 6,000 oz of gold, to be processed on atrial basis, by Celtic at its Suzdal BIOX(R) plant in Kazakhstan. The Companyalso announced that, if the initial shipments proved successful, it intended topurchase up to an additional 120,000 tonnes of concentrates from Hellas Gold.The Company has been very satisfied by the results of the trial and is thereforeannouncing an agreement to purchase a further 50,000 tonnes of concentrates,with shipments expected to be completed by the end of September 2009. The Company operates the only BIOX(R) plant in the FSU for the treatment ofrefractory sulphide ores and in addition to treating ore produced at its Suzdalmine, it will be utilising available BIOX(R) capacity to produce more gold. Suzdal has produced over 28,599 oz of gold in the last three months, whichincludes 11,780 oz produced in September, at an average sale price of US$718 peroz. Kevin Foo, Managing Director of Celtic, said, "We have been delighted with theresults of our initial trial to process third party concentrates at our SuzdalBIOX(R) plant. This agreement is a significant step forward in our strategy tocapitalise on our technology advantages at Suzdal and we are also looking atother third party concentrate opportunities within Kazakhstan and Russia, asmany refractory gold ores remain unexploited." Contact information: Kevin Foo / Jonathan Scott-BarrettCeltic Resources Holdings PlcTel: + 44 (0)20 7921 8800Investors@celtic resources.com Leesa Peters / Jane StaceyConduit PRTel: +44 (0)20 7429 6606 / (0)792 292 3306leesa@conduitpr.com Anthony CardewCardew GroupTel: +44 (0)20 7930 0777anthony.cardew@cardewgroup.com Strand Partners LimitedSimon RaggettStuart FaulknerTel: +44 (0)20 7409 3494 About the Suzdal BIOX(R) plant: Celtic has successfully developed the first BIOX(R) plant for treatment ofrefractory sulphide ores in the FSU at its Suzdal mine in Kazakhstan. The plantuses a sulphide oxidation process for recovering gold from refractory ores orconcentrates. The process utilises a mixed population of naturally occurringbacteria, that are present in all sulphide ores, to break down the sulphidemineral matrix, thereby liberating the occluded gold for subsequent cyanidation. The BIOX(R) process acts as an alternative to conventional processes of roastingand pressure oxidation and offers advantages of reduced capital cost, simplicityof operations, robustness and very low environmental impact. Any person who is the holder of 1 per cent. or more of any class of shares inCeltic may be required to make disclosures pursuant to Rule 8.3 of the IrishTakeover Panel Act, 1997, Takeover Rules 2001 to 2006. The Directors of Celtic accept responsibility for the information contained inthis announcement and to the best of their knowledge and belief (having takenall reasonable care to ensure that such is the case), the information containedin this announcement is in accordance with the facts and, where appropriate,does not omit anything likely to affect the import of such information. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
8th Jun 20265:50 pmRNSPDMR Dealing
1st Jun 20267:00 amRNSInterim Results
19th May 20267:00 amRNSInterim Results Investor Presentation
24th Apr 20262:46 pmRNSTR-1 Notification
22nd Apr 20267:00 amRNSH1 Trading Update
17th Apr 20268:00 amRNSExcercise of Options, Total Voting Rights
14th Apr 20267:00 amRNSCFO Joining Date and Date of Trading Update
9th Apr 202611:43 amRNSTR-1 Notification
27th Mar 20267:00 amRNSTR-1 Notification
26th Mar 20267:00 amRNS-RAchieves "Diamond-level" Open API Certification
5th Mar 202611:44 amRNSGrant of Options
19th Feb 20263:38 pmRNSResult of AGM
18th Feb 20267:00 amRNSNotification of Major Interest in Cerillion
13th Feb 202610:24 amRNSExercise of Options, Total Voting Rights
6th Feb 202610:37 amRNSExercise of Options, TVR, Block Admission Return
2nd Feb 202612:45 pmRNSExercise of Options and Total Voting Rights
28th Jan 20267:00 amRNSBoard Change - CFO Transition
14th Jan 20266:15 pmRNSExcercise of Options and Share Purchase
12th Jan 20269:15 amRNSPosting of Report and Accounts & Notice of AGM
8th Jan 20267:00 amRNSMajor Contract Win
2nd Dec 20255:19 pmRNSTR-1 Notification
24th Nov 20255:56 pmRNSExcercise of Options, PDMR Dealing
24th Nov 20257:00 amRNSFinal Results
3rd Nov 20257:00 amRNSNotice of Final Results
29th Oct 20257:00 amRNS-RLaunch of Cerillion 25.2
23rd Oct 20258:01 amRNSDirector/PDMR Shareholding
23rd Oct 20257:00 amRNSFull Year Trading Update
25th Sep 20257:00 amRNS-RNamed in IDC MarketScape 2025 Assessment
8th Sep 20257:00 amRNSMajor follow-on contracts worth £17.3m
2nd Sep 20257:00 amRNS-RCerillion Recognised in two Gartner Reports
30th Jul 20257:00 amRNSExercise of Options, PDMR dealing and TVR
2nd Jul 20251:14 pmRNSEmployee Share Option Scheme and PDMR dealing
16th Jun 20257:00 amRNSTR-1 Notification
13th Jun 20257:47 amRNSPDMR shareholding - replacement
12th Jun 20251:50 pmRNSResult of Secondary Share Sale
11th Jun 20254:54 pmRNSProposed Secondary Placing
10th Jun 20256:30 pmRNSPDMR Shareholding
5th Jun 20257:37 amRNSDirector/PDMR Shareholding
19th May 20257:00 amRNSInterim Results
16th May 20251:29 pmRNSResult of General Meeting
12th May 20257:00 amRNSNotice of Results and Investor Presentation
30th Apr 20259:06 amRNSNotice of General Meeting
29th Apr 20253:51 pmRNSTR-1 Notification
14th Apr 20257:00 amRNSHalf-year Trading Update
17th Mar 20257:00 amRNSShare Purchase
13th Feb 20254:25 pmRNSResult of AGM
24th Jan 20259:51 amRNSPDMR Shareholding
22nd Jan 20259:35 amRNSPDMR Shareholding
20th Jan 20257:00 amRNSMajor New Contract
15th Jan 20257:00 amRNSShare purchase

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.